胸部恶性肿瘤中免疫检查点抑制剂相关的免疫不良反应：聚焦于非小细胞肺癌患者。
Immune-related adverse events with immune checkpoint inhibitors in thoracic malignancies: focusing on non-small cell lung cancer patients.
作者信息
Remon Jordi, Mezquita Laura, Corral Jesús, Vilariño Noelia, Reguart Noemi
机构信息
Medical Oncology Department, Hospital Vall d'Hebron, Passeig de la Vall d'Hebron, Barcelona, Spain.
Gustave Roussy, Département de Médecine Oncologique, Université Paris-Saclay, Villejuif, France.
出版信息
J Thorac Dis. 2018 May;10(Suppl 13):S1516-S1533. doi: 10.21037/jtd.2017.12.52.
Abstract
Immune checkpoint inhibitors (ICIs) have revolutionized treatment landscape among non-small cell lung cancer (NSCLC) patients in first- and second-line setting, and may become soon new treatment options in other thoracic malignancies such as small cell lung cancer (SCLC) or mesothelioma. The use of these drugs has indubitably changed the toxicity profile the oncologists are familiar with, and new spectra of immune-related adverse events are being reported with the widespread use of immunotherapies in solid tumors. Clinical management and understanding of immune-related adverse events is new and complex but expertise is still limited. In this review, we are summarizing the incidence and management of main side effects related to ICIs focusing on NSCLC patients.
摘要
免疫检查点抑制剂（ICIs）彻底改变了非小细胞肺癌（NSCLC）患者一线和二线治疗的格局，并且可能很快成为其他胸部恶性肿瘤（如小细胞肺癌（SCLC）或间皮瘤）的新治疗选择。这些药物的使用无疑改变了肿瘤学家所熟悉的毒性特征，随着免疫疗法在实体瘤中的广泛应用，与免疫相关的不良事件的新谱正在被报道。免疫相关不良事件的临床管理和理解是新的且复杂的，但专业知识仍然有限。在本综述中，我们总结了与ICIs相关的主要副作用的发生率和管理，重点关注NSCLC患者。
相似文献
1
Immune-related adverse events with immune checkpoint inhibitors in thoracic malignancies: focusing on non-small cell lung cancer patients.胸部恶性肿瘤中免疫检查点抑制剂相关的免疫不良反应：聚焦于非小细胞肺癌患者。
J Thorac Dis. 2018 May;10(Suppl 13):S1516-S1533. doi: 10.21037/jtd.2017.12.52.
2
Old but gold: the role of drug combinations in improving response to immune check-point inhibitors in thoracic malignancies beyond NSCLC.旧药新用：联合用药在提高非小细胞肺癌以外的胸部恶性肿瘤对免疫检查点抑制剂反应中的作用
Explor Target Antitumor Ther. 2021;2(1):1-25. doi: 10.37349/etat.2021.00030. Epub 2021 Feb 28.
3
Optimal management of immune-related adverse events resulting from treatment with immune checkpoint inhibitors: a review and update.免疫检查点抑制剂治疗相关免疫相关不良事件的最佳管理：综述与更新。
Int J Clin Oncol. 2018 Jun;23(3):410-420. doi: 10.1007/s10147-018-1259-6. Epub 2018 Mar 7.
4
Immune checkpoint inhibitors in non-small cell lung cancer (NSCLC): Approaches on special subgroups and unresolved burning questions.免疫检查点抑制剂在非小细胞肺癌（NSCLC）中的应用：特殊亚组人群方法和未解决的热点问题。
Cancer Treat Rev. 2018 Mar;64:21-29. doi: 10.1016/j.ctrv.2018.02.002. Epub 2018 Feb 8.
5
Traditional Treatment Approaches and Role of Immunotherapy in Lung Malignancy and Mesothelioma.传统治疗方法与免疫疗法在肺癌和间皮瘤中的作用。
Cancer Treat Res. 2023;185:79-89. doi: 10.1007/978-3-031-27156-4_5.
6
Immune Checkpoint Inhibitors in Thoracic Malignancies: Review of the Existing Evidence by an IASLC Expert Panel and Recommendations.免疫检查点抑制剂在胸部恶性肿瘤中的应用：IASLC 专家小组对现有证据的综述及推荐意见
J Thorac Oncol. 2020 Jun;15(6):914-947. doi: 10.1016/j.jtho.2020.03.006. Epub 2020 Mar 14.
7
[Immune-related Adverse Events Induced by ICIs in Advanced NSCLC:
A Meta-analysis and Systematic Review].[免疫检查点抑制剂诱导的晚期非小细胞肺癌免疫相关不良事件：一项荟萃分析与系统评价]
Zhongguo Fei Ai Za Zhi. 2020 Sep 20;23(9):772-791. doi: 10.3779/j.issn.1009-3419.2020.104.07. Epub 2020 Aug 5.
8
Neurological Adverse Events Induced by Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Current Perspectives and New Development.免疫检查点抑制剂在非小细胞肺癌中引起的神经学不良事件：当前观点与新进展
Clin Med Insights Oncol. 2021 Nov 24;15:11795549211056261. doi: 10.1177/11795549211056261. eCollection 2021.
9
The landscape of immune checkpoint inhibitor therapy in advanced lung cancer.晚期肺癌中免疫检查点抑制剂治疗的概况
BMC Cancer. 2021 Aug 28;21(1):968. doi: 10.1186/s12885-021-08662-2.
10
Squamous cell carcinoma of the lung: improving the detection and management of immune-related adverse events.肺癌鳞状细胞癌：改善免疫相关不良事件的检测与管理
Expert Rev Anticancer Ther. 2022 Feb;22(2):203-213. doi: 10.1080/14737140.2022.2029414. Epub 2022 Jan 26.
引用本文的文献
1
Lichenoid drug reaction after ipilimumab/nivolumab combination therapy: A case report.伊匹木单抗/纳武单抗联合治疗后发生苔藓样药物反应：一例报告。
SAGE Open Med Case Rep. 2023 Dec 20;11:2050313X231213927. doi: 10.1177/2050313X231213927. eCollection 2023.
2
An assessment of extended pembrolizumab dosing in advanced non-small-cell lung cancer in the COVID-19 pandemic.评估 COVID-19 大流行期间晚期非小细胞肺癌中扩展剂量的 pembrolizumab。
Immunotherapy. 2023 Aug;15(12):921-932. doi: 10.2217/imt-2022-0257. Epub 2023 Jul 11.
3
Predicting response and toxicity to immune checkpoint inhibitors in lung cancer using antibodies to frameshift neoantigens.使用针对移码新抗原的抗体预测肺癌对免疫检查点抑制剂的反应和毒性。
J Transl Med. 2023 May 22;21(1):338. doi: 10.1186/s12967-023-04172-w.
4
Predicting survival of NSCLC patients treated with immune checkpoint inhibitors: Impact and timing of immune-related adverse events and prior tyrosine kinase inhibitor therapy.预测接受免疫检查点抑制剂治疗的非小细胞肺癌患者的生存率：免疫相关不良事件及既往酪氨酸激酶抑制剂治疗的影响和时机
Front Oncol. 2023 Feb 13;13:1064169. doi: 10.3389/fonc.2023.1064169. eCollection 2023.
5
Immune Checkpoint Inhibitors Induced Hepatotoxicity; Gastroenterologists' Perspectives.免疫检查点抑制剂所致肝毒性：胃肠病学家的观点
Middle East J Dig Dis. 2022 Apr;14(2):244-253. doi: 10.34172/mejdd.2022.279. Epub 2022 Apr 30.
6
Association between immune-mediated adverse events and efficacy in metastatic non-small-cell lung cancer patients treated with durvalumab and tremelimumab.度伐利尤单抗和替西木单抗治疗转移性非小细胞肺癌患者的免疫相关不良事件与疗效的相关性。
Front Immunol. 2022 Nov 3;13:1026964. doi: 10.3389/fimmu.2022.1026964. eCollection 2022.
7
Spontaneous bacterial peritonitis in hepatocellular carcinoma after PD-1 inhibitor therapy: two clinical cases.PD-1抑制剂治疗后肝细胞癌并发自发性细菌性腹膜炎：两例临床病例
Heliyon. 2022 Oct 25;8(11):e11248. doi: 10.1016/j.heliyon.2022.e11248. eCollection 2022 Nov.
8
Peripheral absolute eosinophil count identifies the risk of serious immune-related adverse events in non-small cell lung cancer.外周血嗜酸性粒细胞绝对计数可识别非小细胞肺癌中严重免疫相关不良事件的风险。
Front Oncol. 2022 Oct 13;12:1004663. doi: 10.3389/fonc.2022.1004663. eCollection 2022.
9
Human Lactoferrin Synergizes with Etoposide to Inhibit Lung Adenocarcinoma Cell Growth While Attenuating Etoposide-Mediated Cytotoxicity of Human Endothelial Cells.人乳铁蛋白与依托泊苷协同抑制肺腺癌细胞生长，同时减轻依托泊苷对人内皮细胞的细胞毒性。
Biomedicines. 2022 Sep 28;10(10):2429. doi: 10.3390/biomedicines10102429.
10
Safety and efficacy of atezolizumab with rituximab and CHOP in previously untreated diffuse large B-cell lymphoma.阿替利珠单抗联合利妥昔单抗和 CHOP 方案治疗未经治疗的弥漫性大 B 细胞淋巴瘤的安全性和有效性。
Blood Adv. 2023 Apr 25;7(8):1488-1495. doi: 10.1182/bloodadvances.2022008344.
本文引用的文献
1
Drug-Related Pneumonitis in the Era of Precision Cancer Therapy.精准癌症治疗时代的药物相关性肺炎
JCO Precis Oncol. 2017 May 26;1. doi: 10.1200/PO.17.00026. eCollection 2017.
2
Safety of Programmed Death-1 Pathway Inhibitors Among Patients With Non-Small-Cell Lung Cancer and Preexisting Autoimmune Disorders.程序性死亡-1 通路抑制剂在患有非小细胞肺癌和既往自身免疫性疾病患者中的安全性。
J Clin Oncol. 2018 Jul 1;36(19):1905-1912. doi: 10.1200/JCO.2017.77.0305. Epub 2018 May 10.
3
Clinical and Molecular Characteristics Associated With Survival Among Patients Treated With Checkpoint Inhibitors for Advanced Non-Small Cell Lung Carcinoma: A Systematic Review and Meta-analysis.接受检查点抑制剂治疗的晚期非小细胞肺癌患者的生存相关临床和分子特征：系统评价和荟萃分析。
JAMA Oncol. 2018 Feb 1;4(2):210-216. doi: 10.1001/jamaoncol.2017.4427.
4
A Phamacoeconomic Analysis of Personalized Dosing vs Fixed Dosing of Pembrolizumab in Firstline PD-L1-Positive Non-Small Cell Lung Cancer.帕博利珠单抗一线治疗 PD-L1 阳性非小细胞肺癌的个体化剂量与固定剂量的药物经济学分析。
J Natl Cancer Inst. 2017 Nov 1;109(11). doi: 10.1093/jnci/djx063.
5
Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non-Small-Cell Lung Cancer.免疫相关不良反应与纳武利尤单抗治疗非小细胞肺癌疗效的相关性。
JAMA Oncol. 2018 Mar 1;4(3):374-378. doi: 10.1001/jamaoncol.2017.2925.
6
Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-analysis.不同免疫检查点抑制剂方案应用后内分泌功能障碍的发生率：系统评价和荟萃分析。
JAMA Oncol. 2018 Feb 1;4(2):173-182. doi: 10.1001/jamaoncol.2017.3064.
7
Comparison of the toxicity profile of PD-1 versus PD-L1 inhibitors in non-small cell lung cancer: A systematic analysis of the literature.比较 PD-1 与 PD-L1 抑制剂在非小细胞肺癌中的毒性特征：文献系统分析。
Cancer. 2018 Jan 15;124(2):271-277. doi: 10.1002/cncr.31043. Epub 2017 Sep 28.
8
Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review.肿瘤和免疫检查点抑制剂相关不良反应的分类特异性模式：系统评价。
Ann Oncol. 2017 Oct 1;28(10):2377-2385. doi: 10.1093/annonc/mdx286.
9
Endocrinopathies with use of cancer immunotherapies.癌症免疫疗法相关的内分泌疾病。
Clin Endocrinol (Oxf). 2018 Feb;88(2):327-332. doi: 10.1111/cen.13483. Epub 2017 Oct 9.
10
Early Immune-Related Adverse Events and Association with Outcome in Advanced Non-Small Cell Lung Cancer Patients Treated with Nivolumab: A Prospective Cohort Study.纳武利尤单抗治疗晚期非小细胞肺癌患者的早期免疫相关不良事件与结局的相关性：一项前瞻性队列研究。
J Thorac Oncol. 2017 Dec;12(12):1798-1805. doi: 10.1016/j.jtho.2017.08.022. Epub 2017 Sep 20.
Zotero 插件